BTG gene expression in the p53-dependent and -independent cellular response to DNA damage

Molecular Carcinogenesis

Volumn 27, Issue 2, 2000, Pages 57-64

  Cortes, Ulrich ^a   Moyret Lalle, Caroline ^a   Falette, Nicole ^a   Duriez, Cyril ^a   El Ghissassi, Fatiha ^a   Barnas, Christophe ^b   Morel, Anne Pierre ^a   Hainaut, Pierre ^b   Magaud, Jean Pierre ^a   Puisieux, Alain ^a  

^a CENTRE LÉON BÉRARD   (France)

^b INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

Author keywords

BTG1; BTG2 TIS21; BTG3; DNA damage; P53; Tob

Indexed keywords

PROTEIN P53;

APOPTOSIS; ARTICLE; DNA DAMAGE; GENE EXPRESSION; GENOTOXICITY; HUMAN; HUMAN CELL; MAMMAL CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN METHYLATION; PROTEIN MODIFICATION; PROTEIN PROCESSING; SIGNAL TRANSDUCTION; STRUCTURAL GENE;

MAMMALIA;

EID: 0033966875     PISSN: 08991987     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2744(200002)27:2<57::AID-MC1>3.0.CO;2-I     Document Type: Article

References (26)

1. Rimokh R, Rouault JP, Wahbi K, et al. A chromosome 12 coding region is juxtaposed to the MYC protooncogene locus in a t(8;12)(q24;q22) translocation in a case of B-cell chronic lymphocytic leukemia. Genes Chromosomes Cancer 1991;3:24-36.
2. Rouault JP, Rimokh R, Tessa C, et a. BTG1, a member of a new family of antiproliferative genes. EMBO J 1992;11: 1663-1670.
3. Rouault JP, Falette N, Guéhenneux F, et al. Identification of BTG2, an antiproliferative p53-dependent component of the DNA damage cellular response pathway. Nat Genet 1996;14:482-486.
4. Matsuda S, Kawamura-Tsuzuku J, Ohsugi M, et al. Tob, a novel protein that interacts with p185erbB2, is associated with anti-proliferative activity. Oncogene 1996;12: 705-713.
5. Guchenneux F, Duret L, Callanan MB, et al. Cloning of the mouse BTG3 gene and definition of a new gene family (the BTG family) involved in the negative control of the cell cycle. Leukemia 1997;11:370-375.
6. Bradbury A, Possenti R, Shooter EM, Tirone F. Molecular cloning of PC3, a putatively secreted protein whose mRNA is induced by nerve growth factor and depolarization. Proc Natl Acad Sci USA 1991;88:3353-3357.
7. Fletcher BS, Lim RW, Varnum BC, Kujubu DA, Koski RA, Hershman HR. Structure and expression of TIS21, a primary response gene induced by growth factors and tumor promoters. J Biol Chem 1991;266:14511-14518.
8. Montagnoli A, Guardavaccaro D, Starace G, Tirone F. Overexpression of the nerve growth factor-inducible PC3 immediate early gene is associated with growth inhibition. Cell Growth Differ 1996;7:1327-1336.
9. Yoshida Y, Matsuda S, Ikematsu, et al. ANA, a novel member of Tob/BTG1 family, is expressed in the ventricular zone of the developing central nervous system. Oncogene 1996;16:2687-2693.
10. Lim IK, Lee MS, Ryu MS, et al. Induction of growth inhibition of 293 cells by downregulation of the cyclin E and cyclin-dependent kinase 4 proteins due to overexpression of TIS21. Mol Carcinog 1998;23:25-35.
11. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991;51:6304-6311.
12. Clarke AR, Purdie CA, Harrison DJ, et al. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 1993;362:849-852.
13. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997;88:323-331.
14. El-Diery WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993;75: 817-825.
15. Shaulian E, Zauberman A, Ginsberg D, Oren M. Identification of a minimal transforming domain of p53: Negative dominance through abrogation of sequence-specific DNA binding. Mol Cell Biol 1992;12:5581-5592.
16. Bacus SS, Yarden Y, Oren M, et al. Neu differentiation factor (Heregulin) activates a p53-dependent pathway in cancer cells. Oncogene 1996;12:2535-2547.
17. Puisieux A, Ponchel F, Ozturk M. p53 as a growth suppressor gene in HBV-related hepatocellular carcinoma cells. Oncogene 1993;8:487-490.
18. Nishihira T, Hashimoto Y, Katayama M, Mori S, Kuroki T. Molecular and cellular features of esophagal cancer cells. J Cancer Res Clin Oncol 1993;119:441-449.
19. Guillot C, Falette N, Courtois S, et al. Alteration of p53 damage response by tamoxifen treatment. Clin Cancer Res 1996;2:1439-1444.
20. Puisieux A, Galvin K, Troalen F, et al. Retinoblastoma and p53 tumor suppressor genes in human hepatoma cell lines. FASEB J 1993;7:1407-1413.
21. Johnson M, Dimitrov D, Votja PJ, et al. Evidence for a p53-independent pathway for upregulation of SDI1/CIP1/WAF1/ p21 RNA in human cells. Mol Carcinog 1994;11:59-64
22. Rolley N, Butcher S, Milner J. Specific DNA binding by different classes of human p53 mutants. Oncogene 1995;11:763-770.
23. Varnum BC, Reddy ST, Koski RA, Hershman HR. Synthesis, degradation, and subcellular localization of proteins encoded by the primary response genes TIS7/PC4 and TIS21/PC3. J Cell Physiol 1994;158:205-213.
24. Iacopetti P, Barsacchi G, Tirone F, Maffei L, Cremisi F. Developmental expression of PC3 gene is correlated with neuronal cell birthday. Mech Dev 1994;47:127-137.
25. Lin WJ, Gary JD, Yang MC, Clarke S, Hershman HR. The mammalian immediate-early TIS21 protein and the leukemia-associated BTG1 protein interact with a protein-arginine N-methyltransferase. J Biol Chem 1996;271: 15034-15044.
26. Aletta JM, Cimato TR, Ettinger MJ. Protein methylation: a signal event in post-translational modification. Trends Biochem Sci 1998;23:89-91.